vorinostat has been researched along with Adenocarcinoma of Lung in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Adenocarcinoma of Lung: A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the potential drug combinations that interact the most with hub genes and hence have the most potential to reverse the disease process." | 3.01 | Drug repurposing based on differentially expressed genes suggests drug combinations with possible synergistic effects in treatment of lung adenocarcinoma. ( Teimourian, S; Yesharim, L, 2023) |
| " Vorinostat combined with brigatinib significantly improved EGFR-TKI sensitivity to EGFR C797S by inducing EGFR-dependent cell death and may be a promising therapy in treating C797S-resistant lung adenocarcinomas." | 1.62 | Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer. ( Chang, YH; Chang, YL; Chung, WC; Ho, CC; Huang, KY; Kao, SH; Lin, CA; Lin, CY; Lin, YC; Shih, CC; Shih, JY; Yang, PC; Yang, SC, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yesharim, L | 1 |
| Teimourian, S | 1 |
| Lin, CY | 1 |
| Huang, KY | 1 |
| Lin, YC | 1 |
| Yang, SC | 1 |
| Chung, WC | 1 |
| Chang, YL | 1 |
| Shih, JY | 1 |
| Ho, CC | 1 |
| Lin, CA | 1 |
| Shih, CC | 1 |
| Chang, YH | 1 |
| Kao, SH | 1 |
| Yang, PC | 1 |
1 review available for vorinostat and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Drug repurposing based on differentially expressed genes suggests drug combinations with possible synergistic effects in treatment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Drug Combinations; Drug Repositioning; Humans; Lung Neoplasms; Vorinostat | 2023 |
1 other study available for vorinostat and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; D | 2021 |